Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. Susan M Bueno , Katia Abarca , Pablo A González , Nicolás Ms Gálvez , Jorge A Soto , Luisa F Duarte , Bárbara M Schultz , Gaspar A Pacheco , Liliana A González , Yaneisi Vázquez , Mariana Ríos , Felipe Melo-González , Daniela Rivera-Pérez , Carolina Iturriaga , Marcela Urzúa , Angélica Dominguez , Catalina A Andrade , Roslye V Berrios , Gisela Canedo-Marroquín , Camila Covián , Daniela Moreno-Tapia , Farides Saavedra , Omar P Vallejos , Paulina Donato , Pilar Espinoza , Daniela Fuentes , Marcela González , Paula Guzmán , Paula Muñoz-Venturelli , Carlos M Pérez , Marcela Potin , Alvaro Rojas , Rodrigo Fasce , Jorge Fernández , Judith Mora , Eugenio Ramírez , Aracelly Gaete-Argel , Aarón Oyarzún-Arrau , Fernando Valiente-Echeverría , Ricardo Soto-Rifo , Daniela Weiskopf , Alessandro Sette , Gang Zeng , Weining Meng , José V González-Aramundiz , Alexis M Kalergis medRxiv : the preprint server for health sciences（2021）
摘要
Ministry of Health of the Chilean Government; Confederation of Production and Commerce, Chile; Consortium of Universities for Vaccines and Therapies against COVID-19, Chile; Millennium Institute on Immunology and Immunotherapy.
更多 查看译文
AI 理解论文
溯源树
样例
